Department of First Clinical Medical College, Lanzhou University, Lanzhou, China.
Eur Rev Med Pharmacol Sci. 2021 Dec;25(23):7409-7417. doi: 10.26355/eurrev_202112_27438.
The purpose of this study was to evaluate the effect of dexmedetomidine administration on myocardial ischemia/reperfusion (I/R) injury in patients undergoing cardiac surgery with cardiopulmonary bypass (CPB).
Online databases including PubMed, the Cochrane Library, Web of Science, Medline, and EMBASE were searched for clinical trials that investigated the application of dexmedetomidine in CPB patients prior to May 2021. A total of 17 studies involving 866 patients were included in this study.
The result of the meta-analysis showed that there was a significant difference in serum creatinine-kinase-MB (CK-MB) between the dexmedetomidine group and the control group at the end of the operation and 24 h after the operation. Compared to the control group, cardiac troponin I (cTn-I) concentration in the dexmedetomidine group was significantly decreased at the end of the operation, 24 h after the operation, and 48 h after the operation. There was also a significant difference between the dexmedetomidine group and the control group in the length of a patient's ICU stay.
Dexmedetomidine can reduce CK-MB and cTn-I concentrations and shorten the length of ICU stays for patients undergoing cardiac surgery with CPB. It can also provide myocardial protection from I/R injury.
本研究旨在评估右美托咪定给药对体外循环（CPB）心脏手术患者心肌缺血/再灌注（I/R）损伤的影响。
检索了 PubMed、Cochrane 图书馆、Web of Science、Medline 和 EMBASE 等在线数据库，以查找截至 2021 年 5 月研究右美托咪定在 CPB 患者中应用的临床试验。共有 17 项研究纳入了 866 例患者。
荟萃分析结果表明，在手术结束时和手术后 24 小时，右美托咪定组与对照组之间的血清肌酸激酶同工酶（CK-MB）存在显著差异。与对照组相比，右美托咪定组在手术结束时、手术后 24 小时和 48 小时时心肌肌钙蛋白 I（cTn-I）浓度显著降低。右美托咪定组与对照组患者 ICU 入住时间也存在显著差异。
右美托咪定可降低 CPB 心脏手术患者 CK-MB 和 cTn-I 浓度，缩短 ICU 入住时间。它还可以提供心肌 I/R 损伤保护。
